AI
Saturday, August 13, 2022 1:14:15 PM
As we already know the bioavailability of the FDC of VASCEPA with rosuvastatin was successfully demonstrated way back in June 2013. https://investor.amarincorp.com/static-files/79b5ce0a-d2e4-4bcd-97f7-54d8e749efeb A typical combination blister pack might look like this:
The morning dose would be the two 1g capsules. The evening dose would be the two 1g V capsules with a statin (rosuvastatin) shell in various doses (5, 10, 20mg etc.) A future Triple-Combo could include the edition of Ezetimide. The next step would be to use the MND-2119 formulation which would eliminate the morning dose completely.
Recent AMRN News
FEATURED Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • Sep 4, 2024 9:02 AM
FEATURED Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • Sep 4, 2024 8:45 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
